shouldnt this news give us a small increase atleast 2 or 3 cents??? we won a lawsuit, we get this news and no push. Do we need better PR? Whazzup?
Anti-parkinsonian and Anti-dyskinetic Efficacy of HE3286 in a Non-human Model of Parkinson’s Disease
HE3286 is an anti-inflammatory drug in phase II clinical trials for other diseases that is being evaluated for treatment of Parkinson’s disease (PD). HE3286 taken orally rapidly enters the brain and targets a molecular pathway that causes the loss of muscle coordination in PD and the loss of muscle control caused by long-term levodopa therapy. Extensive safety testing suggests that HE3286 is safe, and because the drug does not alter normal brain functions, no side effects are anticipated.
Non-human primates with chemically induced PD will be treated for several weeks with placebo, HE3286 or reference drug (amantadine) alone and in combination with levodopa. The subject’s symptoms of PD, such as loss of muscle coordination and reduced mobility, will be monitored using video recordings to aid in the assessment of the drug’s activity.
After several weeks of treatment, high doses of levodopa will be administered to induce a loss of muscle control (levodopa-induced dyskinesia or LID) that almost always besets Parkinson’s patients after lengthy levodopa treatment. The primates will be treated with placebo, HE3286, or amantadine for several weeks and observed for anti-LID efficacy. After anti-LID testing, the brains will be analyzed to determine drug effects on molecular signals that cause PD.
Relevance to Diagnosis/Treatment of Parkinson’s Disease:
HE3286 as a stand-alone PD therapy may improve motor coordination and/or decrease LID, or it may enhance the efficacy of levodopa. HE3286 could be an alternative to levodopa for patients who have developed LID or desire or need to postpone initiation of levodopa therapy. Because HE3286 is a disease-modifying agent with low potential for drug-to-drug interactions, it has the potential to be combined with other disease-modifying agents
Just happened to find this. A Dr. Kenneth Shindler is scheduled for a 15 minute presentation on " HE3286 suppression of experimental optic neuritis " at the annual meeting of the North American Neuro-Ophthalmology in March, 2014. No other information available and probably insignificant, but at least it is something new.
hrongantssir my feeling is rordreds would like to be left alone. There are enough clues out there for all of us to make decisions.
curious, but that message appears to have been dropped. I read it and you were saying take a look at mrna as an examply of possible activity at hrbr. must have gotten someone tweaked I guess.
rordreds: please reply to this. when I read your post the first time I "saw" uncomfortable. reading it again I see you wrote comfortable with what is transpiring. to confirm, you wrote and are "comfortable with what is transiring"?
Thanks rordreds, found the nice write up from the 2011 meeting, which I also assume was the last one. Can you clue me in to what is transpiring? Unless you have information which is considered insider and can not be posted, there really isn't much that the company has put out since it went dark to bring about the feeling of comfortableness. Thank you.
I do like your humor sir. Think much more is planned then we might be able to think of. There was over 158k on the ask; a couple of dimes, while a measly 5k on the bid at .15 They are completely controlling the price and can do whatever they want with the price. Let me ask you this, would you pay 8 million to get only those write offs,and maybe you would, or perhaps you may want to do something with all those preferred shares one day.
rordreds, 'with what is transpiring' sounds ominous. - would you confirm that the shareholder meeting that you attended and wrote about was the one in October, 2011? I have not been given notice for one subsequent to that. thanks.
Been a while. Don't post much as I am comfortable with what is transpiring. I wrote up a bunch of stuff about the last shareholder meeting so it's in here if you search for it.
thanks for this extended reply - yahoo was kind enough to send me a stub of the one that was erased that included the link, so I got a chance to look at that as well. looks as tho, from a timing perspective, parties are now freer to go in new directions. given that one is an airline and the other a biotech, I wouldn't be surprised if travel arrangements are being considered even now. as to the shareholders, well, hmmm...